Expertise in
8
conditions

Jean-yves Y. Pierga

Paris, FR 
Expertise in
8
conditions
Paris, FR 
OverviewLocationsClinical Research

Overview

Jean-yves Pierga practices in Paris, France. Pierga is highly rated in 8 conditions, according to our data. Their top areas of expertise are Breast Cancer, Inflammatory Breast Cancer, Triple-Negative Breast Cancer, HER2 Negative Breast Cancer, and Mastectomy.

Their clinical research consists of co-authoring 250 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Locations

Paris, France
Other Locations
Saint Cloud, France
Boulogne-billancourt, France
Rene, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Prospective Multicenter Open-label, Randomized Phase II Study of Pembrolizumab in Combination With Neoadjuvant EC-Paclitaxel Regimen in HER2-negative Inflammatory Breast Cancer.
A Prospective Multicenter Open-label, Randomized Phase II Study of Pembrolizumab in Combination With Neoadjuvant EC-Paclitaxel Regimen in HER2-negative Inflammatory Breast Cancer.
Enrollment Status: Active_not_recruiting
Publish Date: September 12, 2025
Intervention Type: Drug
Study Drugs: Pembrolizumab Injection, Neoadjuvant EC-Paclitaxel Chemotherapy
Study Phase: Phase 2
Evaluation of Different Analysis Methods for Circulating Tumor Cells, Circulating Endothelial Cell, and Circulating Tumor DNA in Patient Followed for a Tumoral Pathology
Evaluation of Different Analysis Methods for Circulating Tumor Cells, Circulating Endothelial Cell, and Circulating Tumor DNA in Patient Followed for a Tumoral Pathology
Enrollment Status: Completed
Publish Date: August 08, 2025
Intervention Type: Procedure
Study Phase: Not Applicable
EMBER: A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination With Anticancer Therapies for Patients With ER+ Locally Advanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers
EMBER: A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination With Anticancer Therapies for Patients With ER+ Locally Advanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers
Enrollment Status: Active_not_recruiting
Publish Date: June 04, 2025
Intervention Type: Drug
Study Drugs: LY3484356, Abemaciclib, Everolimus, Alpelisib, Trastuzumab, Aromatase Inhibitor
Study Phase: Phase 1
Risk of Infertility Related to Adjuvant Chemotherapy for Early Breast Cancer: Oocyte/Embryo Cryopreservation (CHACRY-1501)
Risk of Infertility Related to Adjuvant Chemotherapy for Early Breast Cancer: Oocyte/Embryo Cryopreservation (CHACRY-1501)
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2025
Intervention Type: Procedure
Study Phase: Not Applicable
Efficacy of Regorafenib as Maintenance Therapy in Non-adipocytic Soft Tissue Sarcoma Having Received First-line Doxorubicin-based Chemotherapy
Efficacy of Regorafenib as Maintenance Therapy in Non-adipocytic Soft Tissue Sarcoma Having Received First-line Doxorubicin-based Chemotherapy
Enrollment Status: Completed
Publish Date: December 10, 2024
Intervention Type: Drug
Study Drug: Regorafenib
Study Phase: Phase 2
Analysis of Circulating Tumor Markers in the Blood
Analysis of Circulating Tumor Markers in the Blood
Enrollment Status: Completed
Publish Date: October 01, 2024
Intervention Type: Biological, Procedure, Other
Study Phase: Not Applicable
A Multicenter, Randomised, Open-label Phase II Study to Evaluate the Clinical Benefit of a Post-operative Treatment Associating Radiotherapy + Nivolumab + Ipilimumab Versus Radiotherapy + Capecitabine for Triple Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Chemotherapy
A Multicenter, Randomised, Open-label Phase II Study to Evaluate the Clinical Benefit of a Post-operative Treatment Associating Radiotherapy + Nivolumab + Ipilimumab Versus Radiotherapy + Capecitabine for Triple Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2024
Intervention Type: Drug
Study Drugs: Nivolumab, Ipilimumab, Capecitabine
Study Phase: Phase 2
Circulating Tumor DNA and Follow-up of BRCA1 Mutation Carriers (CirCa 01)
Circulating Tumor DNA and Follow-up of BRCA1 Mutation Carriers (CirCa 01)
Enrollment Status: Completed
Publish Date: January 31, 2024
Intervention Type: Procedure
Study Phase: Not Applicable
Prospective Construction and Validation of a Prognostic Score to Identify Among Patients With Metastatic Breast Cancer Those Who Benefit From a Third Line Chemotherapy in Terms of Overall Survival
Prospective Construction and Validation of a Prognostic Score to Identify Among Patients With Metastatic Breast Cancer Those Who Benefit From a Third Line Chemotherapy in Terms of Overall Survival
Enrollment Status: Completed
Publish Date: June 13, 2023
Intervention Type: Other
Study Phase: Phase 4
View 8 Less Clinical Trials

250 Total Publications

Corrigendum to "International expert consensus on the clinical integration of circulating tumor cells in solid tumors" [Eur. J. Cancer 231 (2025) 116050].
Corrigendum to "International expert consensus on the clinical integration of circulating tumor cells in solid tumors" [Eur. J. Cancer 231 (2025) 116050].
Journal: European journal of cancer (Oxford, England : 1990)
Published: December 11, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Pierga's expertise for a condition
ConditionClose
View All 13 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile